Caladrius Biosciences Announces Presentations at Multiple Upcoming Conferences in January

BASKING RIDGE, N.J., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider with a therapeutic development pipeline, announces today that Company management and experts will present this month at the Noble Financial Capital Markets Investor Conference, Phacilitate Cell and Gene Therapy World Conference and the Novel Cardiovascular Therapeutics Summit.

Noble Financial Capital Markets 12th Annual Investor Conference

Phacilitate Cell and Gene Therapy World Conference

Session 1

  • Date and Time: Monday, January 25, 2016, 12:50 PM ET
  • Presenter: Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT
  • Topic: Patient-specific cell therapy factory of the future – can you get there from here?

Session 2

  • Date and Time: Monday, January 25, 2016, 3:55 PM ET
  • Panel Chair: Dr. Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius Biosciences; President, PCT
  • Topic: What does commercialization look like?

Session 3

  • Date and Time: Tuesday, January 26, 2016, 4:10 PM ET
  • Presenters: Dr. Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius Biosciences; President, PCT; Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT; Ian Gaudet, Director, Innovation & Engineering, PCT
  • Topic: Getting Commercial: Engineering the Future

Novel Cardiovascular Therapeutics Summit

  • Venue: Hotel Nikko San Francisco, San Francisco, California
  • Website:
  • Date and Time: Thursday, January 28, 2016, 3:30 PM ET
  • Presenter: Dr. Douglas Losordo, Chief Medical Officer and Senior Vice President, Clinical, Medical and Regulatory Affairs, Caladrius Biosciences
  • Topic: Cell Based Therapy for Cardiovascular Disease: A single treatment for long-term modification of disease natural history

About Caladrius Biosciences

Caladrius Biosciences, Inc., through its wholly-owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. Caladrius works with its clients to overcome the fundamental challenges presented by cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. Around this core expertise, Caladrius strategically develops product candidates, which currently include an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation, and holds intellectual property around other cell therapy platform technologies. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding our expected revenues and capital expenditures, personnel reductions, as well as the potential of CLBS03 in the treatment of recent-onset type 1 diabetes and the expected cost savings associated with the termination of the CLBS20 study. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC, including: risks related to: (i) our expected continued losses and negative cash flows; (ii) our anticipated need for substantial additional financing; (iii) the significant costs and management resources required to comply with the requirements of being a public company; (iv) the possibility that a significant market for cell therapy may not emerge; (v) the potential variability in PCT’s revenues; (vi) PCT’s limited manufacturing capacity; (vii) the need to improve manufacturing efficiency at PCT; (viii) the limited marketing staff and budget at PCT; (ix) the logistics associated with the distribution of materials produced by PCT; (x) government regulation; (xi) our intellectual property; (xii) cybersecurity; (xiii) the development, approval and commercialization of our products; (xiv) enrolling patients in and completing, clinical trials; (xv) the variability of autologous cell therapy; (xvi) our access to reagents we use in the clinical development of our cell therapy product candidates; (xvii) the validation and establishment of manufacturing controls; (xviii) the failure to obtain regulatory approvals outside the United States; (xix) our failure to realize benefits relating to “fast track” and “orphan drug” designations; (xx) the failure of our clinical trials to demonstrate the safety and efficacy of our product candidates; (xx) our current lack of sufficient manufacturing capabilities to produce our product candidates at commercial scale; (xxi) our lack of revenue from product sales; (xxii) the commercial potential and profitability of our products; (xxiii) our failure to realize benefits from collaborations, strategic alliances or licensing arrangements; (xxiv) the novelty and expense of the technology used in our cell therapy business; (xxv) the possibility that our competitors will develop and market more effective, safer or less expensive products than our product candidates; (xxvi) product liability claims and litigation, including exposure from the use of our products; (xxvii) our potential inability to retain or hire key employees; and (xxviii) risks related to our capital stock. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

CONTACTS: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email:

Source:Caladrius Biosciences, Inc.